文献速递妇科肿瘤

WEE1抑制剂AZD1775联合卡铂治疗一线治疗后3个月内难治或耐药的TP53突变卵巢癌患者的II期研究

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
PubMed 文献 · J Clin Oncol · 2016-10-28

这项II期研究纳入24例TP53突变、一线铂类治疗后3个月内难治或耐药的卵巢癌患者,接受卡铂(AUC 5 mg/mL·min)联合AZD1775 225 mg口服每日两次、每21天周期用2.5天。21例可评估疗效,总缓解率43%(95%CI 22%–66%),中位无进展生存5.3个月,中位总生存12.6个月。作者认为这是AZD1775增强卡铂对TP53突变肿瘤疗效的首个临床证据,值得进一步开发。

要点

  • 21例可评估患者总缓解率43%(95%CI 22%–66%),含1例(5%)持续完全缓解。
  • 中位无进展生存5.3个月(95%CI 2.3–9.0),中位总生存12.6个月(95%CI 4.9–19.7)。
  • 最常见3/4级不良事件为血小板减少(48%)和中性粒细胞减少(37%)。

核心结论

  • 据作者所知,这是首个提供AZD1775增强卡铂对TP53突变肿瘤疗效的临床证据的报告。
  • 在TP53突变、一线治疗后难治或耐药(<3个月)的卵巢癌患者中观察到的抗肿瘤活性令人鼓舞,值得进一步开发。

研究设计与样本

  • 这是一项证明原理的II期研究,纳入TP53突变、对一线铂类治疗难治或耐药(<3个月)的卵巢癌患者。
  • 患者接受卡铂(曲线下面积5 mg/mL·min)联合AZD1775 225 mg口服每日两次、每21天周期用2.5天,直至疾病进展。
  • 共入组24例患者,其中21例可评估疗效终点。

主要发现

  • AZD1775联合卡铂毒性可控;最常见不良事件为疲乏(87%)、恶心(78%)、血小板减少(70%)、腹泻(70%)和呕吐(48%)。
  • 最常见3级或4级不良事件为血小板减少(48%)和中性粒细胞减少(37%)。
  • 总缓解率为43%(95%CI 22%–66%),包括1例(5%)持续完全缓解。
  • 中位无进展生存期为5.3个月(95%CI 2.3–9.0个月),中位总生存期为12.6个月(95%CI 4.9–19.7个月)。
  • 数据截止时,2例患者持续缓解超过31个月和42个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1 with proof of chemopotentiation in p53-deficient tumors in preclinical models. In a phase I study, the maximum tolerated dose of AZD1775 in combination with carboplatin demonstrated target engagement. We conducted a proof-of-principle phase II study in patients with p53 tumor suppressor gene ( TP53)-mutated ovarian cancer refractory or resistant (< 3 months) to first-line platinum-based therapy to determine overall response rate, progression-free and overall survival, pharmacokinetics, and modulation of phosphorylated cyclin-dependent kinase (CDK1) in skin biopsies. Patients and Methods Patients were treated with carboplatin (area under the curve, 5 mg/mL⋅min) combined with AZD1775 225 mg orally twice daily over 2.5 days every 21-day cycle until disease progression. Results AZD1775 plus carboplatin demonstrated manageable toxicity; fatigue (87%), nausea (78%), thrombocytopenia (70%), diarrhea (70%), and vomiting (48%) were the most common adverse events. The most frequent grade 3 or 4 adverse events were thrombocytopenia (48%) and neutropenia (37%). Of 24 patients enrolled, 21 patients were evaluable for efficacy end points. The overall response rate was 43% (95% CI, 22% to 66%), including one patient (5%) with a prolonged complete response. Median progression-free and overall survival times were 5.3 months (95% CI, 2.3 to 9.0 months) and 12.6 months (95% CI, 4.9 to 19.7), respectively, with two patients with ongoing response for more than 31 and 42 months at data cutoff. Conclusion To our knowledge, this is the first report providing clinical proof that AZD1775 enhances carboplatin efficacy in TP53-mutated tumors. The encouraging antitumor activity observed in patients with TP53-mutated ovarian cancer who were refractory or resistant (< 3 months) to first-line therapy warrants further development.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Leijen S, van Geel RM, Sonke GS, et al. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. J Clin Oncol. 2016. PMID: 27998224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。